IN2015DN01496A - - Google Patents
Download PDFInfo
- Publication number
- IN2015DN01496A IN2015DN01496A IN1496DEN2015A IN2015DN01496A IN 2015DN01496 A IN2015DN01496 A IN 2015DN01496A IN 1496DEN2015 A IN1496DEN2015 A IN 1496DEN2015A IN 2015DN01496 A IN2015DN01496 A IN 2015DN01496A
- Authority
- IN
- India
- Prior art keywords
- cancer
- wilfordii
- organic solvent
- treatment
- chemotherapeutic
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 abstract 6
- 241000830536 Tripterygium wilfordii Species 0.000 abstract 5
- 239000002246 antineoplastic agent Substances 0.000 abstract 5
- 201000011510 cancer Diseases 0.000 abstract 5
- 229940044683 chemotherapy drug Drugs 0.000 abstract 5
- 239000000284 extract Substances 0.000 abstract 5
- 239000003960 organic solvent Substances 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 206010059866 Drug resistance Diseases 0.000 abstract 1
- 230000000973 chemotherapeutic effect Effects 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 238000011275 oncology therapy Methods 0.000 abstract 1
- 235000015398 thunder god vine Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/37—Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261684792P | 2012-08-19 | 2012-08-19 | |
| PCT/US2013/055602 WO2014031543A1 (en) | 2012-08-19 | 2013-08-19 | Tripterygium wilfordii extracts to overcome chemotherapy resistance |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN01496A true IN2015DN01496A (enExample) | 2015-07-03 |
Family
ID=50150329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1496DEN2015 IN2015DN01496A (enExample) | 2012-08-19 | 2013-08-19 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10149876B2 (enExample) |
| EP (1) | EP2888011A4 (enExample) |
| JP (1) | JP6367801B2 (enExample) |
| CN (1) | CN104797296B (enExample) |
| AU (2) | AU2013306058A1 (enExample) |
| CA (1) | CA2880575C (enExample) |
| HK (2) | HK1211888A1 (enExample) |
| IN (1) | IN2015DN01496A (enExample) |
| WO (1) | WO2014031543A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6529138B2 (ja) * | 2013-09-13 | 2019-06-12 | ウェスタン ユニバーシティ オブ ヘルス サイエンス | 化学療法耐性を克服するためのウィルホルリドａの使用 |
| CN111909119B (zh) * | 2020-08-25 | 2023-06-16 | 上海诗丹德标准技术服务有限公司 | 雷公藤来源化合物及其应用和制备方法、药物组合物、杀虫剂 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7570191A (en) | 1990-03-14 | 1991-10-10 | Board Of Regents, The University Of Texas System | Tripterygium wilfordii hook f extracts and components thereof for immunosuppression |
| EP1604661A1 (en) | 2003-02-27 | 2005-12-14 | Teruo Nishida | Remedy for corneal ulcer |
| CN102443039B (zh) | 2010-10-14 | 2013-11-13 | 中国科学院上海药物研究所 | N-取代氨基苯基-14β-氨甲基表雷公藤内酯醇衍生物及其制备方法和用途 |
-
2013
- 2013-08-19 IN IN1496DEN2015 patent/IN2015DN01496A/en unknown
- 2013-08-19 US US14/422,216 patent/US10149876B2/en not_active Expired - Fee Related
- 2013-08-19 EP EP13831724.3A patent/EP2888011A4/en not_active Withdrawn
- 2013-08-19 JP JP2015528556A patent/JP6367801B2/ja not_active Expired - Fee Related
- 2013-08-19 WO PCT/US2013/055602 patent/WO2014031543A1/en not_active Ceased
- 2013-08-19 AU AU2013306058A patent/AU2013306058A1/en not_active Abandoned
- 2013-08-19 CN CN201380043906.5A patent/CN104797296B/zh active Active
- 2013-08-19 HK HK15112784.8A patent/HK1211888A1/xx unknown
- 2013-08-19 HK HK15112587.7A patent/HK1212270A1/xx unknown
- 2013-08-19 CA CA2880575A patent/CA2880575C/en active Active
-
2018
- 2018-01-30 AU AU2018200709A patent/AU2018200709B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US10149876B2 (en) | 2018-12-11 |
| US20150238553A1 (en) | 2015-08-27 |
| AU2018200709B2 (en) | 2019-10-24 |
| JP2015529664A (ja) | 2015-10-08 |
| JP6367801B2 (ja) | 2018-08-01 |
| HK1211888A1 (en) | 2016-06-03 |
| AU2013306058A1 (en) | 2015-02-19 |
| EP2888011A4 (en) | 2016-01-27 |
| AU2018200709A1 (en) | 2018-02-22 |
| CN104797296A (zh) | 2015-07-22 |
| CA2880575A1 (en) | 2014-02-27 |
| WO2014031543A1 (en) | 2014-02-27 |
| HK1212270A1 (en) | 2016-06-10 |
| CA2880575C (en) | 2023-07-11 |
| CN104797296B (zh) | 2019-12-17 |
| EP2888011A1 (en) | 2015-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ738929A (en) | Methods of treating solid tumors using nanoparticle mtor inhibitor combination therapy | |
| MX2017016491A (es) | Metodos para tratar malignidad hematologica usando terapia combinada de nanoparticulas de inhibidor de objetivo mamifero de la rapamicina (mtor). | |
| NZ729643A (en) | Combination therapy for treating cancer | |
| MY166014A (en) | Combination therapy methods for treating proliferative diseases | |
| WO2016161342A3 (en) | Nitrobenzyl derivatives of anti-cancer agents | |
| MX2019012462A (es) | Terapia combinada. | |
| WO2007084670A8 (en) | Specific therapy using integrin ligands for treating cancer | |
| MY168791A (en) | Carbamate compounds and of making and using same | |
| WO2016025635A3 (en) | Combination therapy for treating cancer | |
| BR112016012713A2 (pt) | Método para tratamento de câncer em um paciente necessitado, e, método de selecionar um paciente para um método de tratamento | |
| WO2008087025A3 (en) | Specific therapy and medicament using integrin ligands for treating cancer | |
| PH12016502354A1 (en) | Pharmaceutical composition | |
| RU2016112608A (ru) | Лечение рака комбинацией плинабулина и таксана | |
| WO2012159085A3 (en) | Compositions and methods for treating and preventing cancer by targeting and inhibiting cancer stem cells | |
| WO2011017534A3 (en) | Treatment of prostate cancer | |
| MX2015010791A (es) | Metodos para tratar el cancer y prevenir la resistencia a farmacos. | |
| MX2017017138A (es) | Conjugados homogeneos especificos de sitio con inhibidores de ksp. | |
| ZA202302155B (en) | Interferon-based cancer treatment method and pharmaceutical composition | |
| PH12016501527A1 (en) | Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient | |
| MX2015015434A (es) | Corroles dirigidas para toxicidad tumoral y rm. | |
| WO2015038896A3 (en) | Wilforlide a for overcoming chemotherapy resistance | |
| IN2015DN01496A (enExample) | ||
| MY197664A (en) | Immunity enhancing agent for cancer by allergin-1 antagonist | |
| HK1259026A1 (zh) | 用於治疗癌症的抗趋除剂的局部递送 | |
| WO2010057596A3 (en) | New therapy and medicament using integrin ligands for treating cancer |